A new ALZ-801 oral treatment can detect the toxin responsible for brain damage linked to Alzheimer’s disease. It can also prevent the toxin from being formed. The treatment now enters the third and final stage of clinical study
Alzheimer’s has been one of the most dreaded diseases out there. It comes at a slow pace when elderly people first start forgetting about tiny details.
However, after a while, it could result in severe memory loss, making people unable to take care of themselves. This is especially painful for the family who sees their loved ones slowly vanishing.
But now there is hope that we could avoid getting to this stage of Alzheimer’s and eventually, cure it completely.
A neurologist, entrepreneur, and CEO of Alzheon, Martin Tolar, has carried out the development of ALZ-801 – the first oral disease-modifying treatment that can diagnose and treat Alzheimer’s up to two decades before the patient notices the first clinical symptoms.
Toxins are slowly making our brains decay
The way how to beat down Alzheimer’s lies in the process of how the disease develops in the human brain.
Various studies suggest that Alzheimer’s can be driven by the production and deposition of a toxin called the β-amyloid peptide (Aβ). But the process is pretty slow.
“It takes around twenty years for the toxin to accumulate in such an amount that it can damage the brain to the level in which first clinical symptoms emerge,” Tolar told Forbes Czech Republic.
“After that, it’s too late to cure it. Once clinical symptoms appear, the brain damage is so severe, that it goes really quick from the state when a person tends to forget small things, to the state in which they are not able to take care of themselves.”
The new ALZ-801 treatment can detect the toxin as well as prevent it from being formed.
Infusion vs. oral treatment
ALZ-801 is not the only promising cure for Alzheimer’s that has been recently developed. But in comparison to other substances, it’s much more comfortable for potential patients.
Its great advantage is that it’s an oral treatment while the other medicaments have to be inserted into the body in a form of infusions.
Not only it’s less practical for patients, but it’s also safer. Because infusions can also lead to other issues such as brain swelling.
ALZ-801 has now entered the third phase of clinical tests which itself is promising.
Tolar has managed to get around $500 million in investments for the cure and believes that if approved, the medicament can generate billions in profit as well as save millions of lives worldwide.
Read more positive news.